[Development of new antileukemic agents].
D015250:Aclarubicin; D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D051379:Mice; D008875:Middle Aged; D009279:Naphthacenes / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; C015019:enocitabine